Curis 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- In the TECAME registrational study of emavucertib plus ibrutinib in relapsed/refractory PCNSL, updated results showed an 86% response rate in BTK-naive patients (6 of 7) and a 26% response rate in salvage-line patients whose disease had progressed on a BTK inhibitor (10 of 39).
- Curis reported a net loss of $8.1 million, or $1.94 per share, for the 3rd quarter of 2026, compared with a net loss of $7.7 million, or $9.86 per share, for the same period in 2025.
- For the 9 months ended September 30th, 2026, Curis reported a net loss of $40.9 million, or $16.77 per share, compared with $26.9 million, or $43.82 per share, for the same period in 2025.
- Research and development expenses were $5.6 million for the 3rd quarter of 2026, compared with $6.4 million for the same period in 2025, and $18.8 million for the 9 months ended September 30th, 2026, compared with $22.4 million for the same period in 2025.
- General and administrative expenses were $3.2 million for the 3rd quarter of 2026, compared with $3.7 million for the same period in 2025, and $11.4 million for the 9 months ended September 30th, 2026, compared with $11.2 million for the same period in 2025.
- Curis had $5 million in cash and cash equivalents as of September 30th, 2026, and approximately 4.1 million shares of common stock outstanding.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Call is being recorded on Thursday, November 12, 2026. I would now like to turn the conference over to your host, Diantha Duvall.
Thank you, and welcome to Curis' third quarter 2026 business update call. Before we begin, I would like to encourage everyone to go to the investor section of our website at www.curis.com to find our third quarter 2026 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me today are Jim Dentzer, President and Chief Executive Officer, Dr. Jonathan Zung, Chief Development Officer, and Dr. Ahmed Hamdy, Chief Medical Officer. We will also be available for a question-and-answer period at the end of the call. I'd now like to turn the call over to Jim.
Thank you, Diantha. Good afternoon, everyone, and welcome to Curis' third quarter business update call. I'll start with PCNSL, our lead program and first NHL study. We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL subtypes. As a reminder, the TakeAim Lymphoma study is a registrational study of emavusertib in combination with ibrutinib in patients with relapsed refractory PCNSL. We reported updated data this quarter for seven BTK-naive patients and 39 salvage line patients whose disease had progressed while on treatment with a BTK inhibitor. The updated data show an 86% response rate in BTKi-naive patients, with six of seven patients achieving a response. For context, it's important to note that published studies of BTK inhibitors in PCNSL have generally shown response rates of 39%-67%.
Clearly, the combination of emavusertib plus BTKi appears to be better than BTKi alone. For salvage line patients, those patients whose disease had progressed while taking a BTK inhibitor, the updated data show a 26% response rate, with 10 of 39 patients responding when treated with the emavusertib plus BTKi combination after they had already progressed on BTKi monotherapy. For context, patients who have failed both frontline therapy and BTKi have a very poor prognosis, with many patients proceeding directly to hospice or best supportive care. That emavusertib is helping patients change that story and reverse their disease is very encouraging. In short, the updated data in both BTKi-naive and salvage line patients provide further evidence of meaningful clinical activity and continue to support the potential for accelerated approval submissions in both the U.S. and Europe.
We look forward to completing full enrollment in this registrational study on schedule in 2027. Now let's turn to CLL, our second NHL study, which was initiated earlier this year. As you recall, last year we engaged with a number of key opinion leaders about which NHL subtype to study after PCNSL. They were intrigued by our early data across multiple NHL subtypes and expressed a particular interest in exploring emavusertib's potential to fundamentally change the frontline treatment paradigm for CLL patients, where the current standard of care is BTK inhibitors. Over the last decade, BTK inhibitors have become standard of care in CLL and NHL because of their ability to block the BCR pathway and help patients achieve objective responses. However, these responses are typically partial responses, not complete remission.
The result is that patients treated with a BTK inhibitor end up having to stay on it in chronic treatment for the rest of their lives. Additionally, because they never achieve complete remission, many of these patients develop BTKi-resistant mutations, and ultimately, their disease progresses. We are looking to improve upon the current standard of care by adding emavusertib to a patient's BTKi regimen, applying a dual blockade to the two biologic pathways driving CLL. This dual blockade, with BTKi blocking the BCR pathway and emavusertib blocking the TLR pathway, can enable patients whose cancer partially responds to a BTK inhibitor to achieve deeper responses with the combination, including the ability to achieve complete remission or undetectable disease and the potential for time-limited treatment.
If we're successful, adding emavusertib to BTKi could change the treatment paradigm in CLL, reducing the risk of developing a treatment-resisting mutation and improving a patient's overall quality of life. The first step in testing this hypothesis in CLL is our proof-of-concept study in patients currently on BTKi monotherapy who have achieved partial remission but have been unable to achieve complete remission or undetectable MRD. We have 11 clinical sites open for enrollment with 12 patients on study, and we look forward to reporting initial data later this year. If the data in CLL are consistent with our previous NHL data, we would hope to see early evidence of anti-cancer activity that could ultimately lead to a reduction of tumor burden and deeper objective responses. I know our clinicians, and especially our patients, are excited about the potential of emavusertib to increase the efficacy of BTK inhibitors in frontline CLL.
In summary, we have made meaningful progress across both NHL studies this year. In PCNSL, our lead NHL program, the updated data show consistent efficacy and are very encouraging as we advance toward full enrollment and a potential first regulatory submission. In CLL, our second NHL program, we remain on track to report initial clinical data by year-end, which is now only a few weeks away. With that, I'll turn the call back to Diantha for the financial update.
Diantha? Thank you, Jim. Curis reported a net loss of $8.1 million, or $1.94 per share, for the third quarter of 2026, as compared to a net loss of $7.7 million, or $9.86 per share, for the same period in 2025.
Curis reported a net loss of $40.9 million, or $16.77 per share, for the nine months ended September 30th, 2026, as compared to a net loss of $26.9 million, or $43.82 per share, for the same period in 2025. Research and development expenses were $5.6 million for the third quarter of 2026, as compared to $6.4 million for the same period in 2025. The decrease was primarily attributable to lower employee-related costs, partially offset by an increase in clinical costs. Research and development expenses were $18.8 million for the nine months ended September 30th, 2026, as compared to $22.4 million for the same period in 2025.
General and administrative expenses were $3.2 million for the third quarter of 2026, as compared to $3.7 million for the same period in 2025. The decrease was primarily attributable to lower employee-related costs, partially offset by an increase in legal costs. General and administrative expenses were $11.4 million for the nine months ended September 30th, 2026, as compared to $11.2 million for the same period in 2025. Curis' cash and cash equivalents were $5 million as of September 30th, 2026, and the company had approximately 4.1 million shares of common stock outstanding. Based on our current operating plan, we believe that our existing cash and cash equivalents, along with the financing from October, should enable us to fund our existing operations into 2027. With that, I'd like to turn the call over for questions.
Operator? Thank you. Ladies and gentlemen, we will now begin the question-and-answer session.
Should you have a question, please press star, then one on your touch-tone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, you can press star followed by two. If you're using a speakerphone, please lift the handset first before pressing any keys. We have our first question from Yale Jen with Laidlaw.
Good afternoon, and thanks for taking the questions, and congrats on all the progresses. Just two from us. The first one is that in terms of the 12 patients in the CLL study, for the data release in December, how many of those potentially be available for reporting in terms of completing a certain number of treatment cycles? Then I have a follow-up.
Okay. First, thank you, Yale, for joining the call. Appreciate it. The 12 patients, as you can imagine, came on at very different time points. Our goal at this point in time is to report as much data as we can at the time of the release, and that means, of course, we will have more mature data, patients who have been on drug for three or four cycles, as well as potentially some patients who have only got data in for a cycle or two. Exactly how many patients fit in which category, of course, we are going to release the data in real time, and we will give as much data as we have. I hope that is helpful.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
